Skip to main content
TipRanks
Go Ultimate75% OFF

Compare Clinuvel Pharmaceuticals (UR9) vs. Competitors

0 Followers

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
CH:UR9Clinuvel Pharmaceuticals CHF 4.26CHF 213.59M11.12-25.85%Moderate BuyUnlock the CH:UR9 analyst price target with TipRanks PremiumCH:UR9Unlock the CH:UR9 top-analyst price target with TipRanks Premium
AU:ACRAcrux AUD 0.01AUD 5.51M-6.43-33.33%―Unlock the AU:ACR analyst price target with TipRanks PremiumCH:UR9 vs AU:ACRUnlock the AU:ACR top-analyst price target with TipRanks Premium
AU:SPLStarpharma Holdings LimitedAUD 0.43AUD 197.99M-24.85-1.85%―Unlock the AU:SPL analyst price target with TipRanks PremiumCH:UR9 vs AU:SPLUnlock the AU:SPL top-analyst price target with TipRanks Premium
AU:PYCPYC Therapeutics LimitedAUD 1.92AUD 1.96B-31.9864.80%Strong BuyUnlock the AU:PYC analyst price target with TipRanks PremiumCH:UR9 vs AU:PYCUnlock the AU:PYC top-analyst price target with TipRanks Premium
AU:BOTBotanix Pharmaceuticals LimitedAUD 0.01AUD 24.86M-0.28-92.31%Moderate BuyUnlock the AU:BOT analyst price target with TipRanks PremiumCH:UR9 vs AU:BOTUnlock the AU:BOT top-analyst price target with TipRanks Premium
AU:BIOBiome Australia LtdAUD 0.38AUD 89.09M22.67-17.39%Moderate BuyUnlock the AU:BIO analyst price target with TipRanks PremiumCH:UR9 vs AU:BIOUnlock the AU:BIO top-analyst price target with TipRanks Premium

Performance Comparison

-100%-50%0%50%100%150%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
CH:UR9Clinuvel Pharmaceuticals 4.26-1.49-25.85%
AU:ACRAcrux 0.01-0.00-33.33%
AU:SPLStarpharma Holdings Limited0.420.025.20%
AU:PYCPYC Therapeutics Limited1.920.6348.56%
AU:BOTBotanix Pharmaceuticals Limited0.01-0.12-92.00%
AU:BIOBiome Australia Ltd0.38-0.09-18.28%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts